Celecoxib in Rheumatoid Arthritis Management

Introduction to Celecoxib Use

The American College of Rheumatology guideline positions DMARDs, biologic agents, and tofacitinib as the cornerstone treatments for controlling disease activity and preventing joint damage in RA, with celecoxib not being a primary disease-modifying therapy 1

Celecoxib should never replace conventional or biologic DMARDs as primary RA therapy, according to the American College of Rheumatology 1
The American College of Rheumatology recommends using celecoxib for short-term symptom control while DMARDs are being optimized or during disease flares, but not as a substitute for DMARDs 1, 3

Celecoxib is contraindicated in patients with NYHA Class III-IV heart failure due to increased mortality risk, as noted by the British Journal of Dermatology 5
Concomitant use of celecoxib with low-dose aspirin often negates the GI-sparing advantages of celecoxib over traditional NSAIDs, according to Clinical Gastroenterology and Hepatology 4
Blood pressure increases can occur with celecoxib, though effects are generally less than with some other coxibs, as reported by Clinical Gastroenterology and Hepatology 4

The American College of Rheumatology suggests celecoxib is most appropriate for RA patients who require symptomatic relief while on DMARD therapy, have high risk for NSAID-induced GI toxicity, or are unresponsive to or intolerant of traditional NSAIDs 1, 3
Patients on celecoxib therapy should be monitored for blood pressure increases, as recommended by Clinical Gastroenterology and Hepatology 4
The need for continued NSAID therapy, such as celecoxib, should be reassessed regularly as part of a treat-to-target approach, according to Praxis Medical Insights 2, 3